KOLLTAN PHARMACEUTICALS
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
KOLLTAN PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2007-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.kolltan.com
Total Employee:
11+
Status:
Active
Contact:
203-773-3000
Email Addresses:
[email protected]
Total Funding:
146 M USD
Technology used in webpage:
IPhone / Mobile Compatible Sectigo SSL Sectigo Domain SSL Network Solutions DNS AdBlock Acceptable Ads Akamai Adobe Dreamweaver Citrix NetScaler Network Solutions Network Solutions Email Hosting
Similar Organizations
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Adastra Pharmaceuticals
Adastra Pharmaceuticals provides responsible solutions to advance patient care in oncology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fidelity
Fidelity investment in Series D - Kolltan Pharmaceuticals
KLP Enterprises
KLP Enterprises investment in Series D - Kolltan Pharmaceuticals
Deerfield
Deerfield investment in Series D - Kolltan Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - Kolltan Pharmaceuticals
Purdue Pharma
Purdue Pharma investment in Series D - Kolltan Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series D - Kolltan Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Kolltan Pharmaceuticals
Tichenor Ventures
Tichenor Ventures investment in Series B - Kolltan Pharmaceuticals
Auven Therapeutics
Auven Therapeutics investment in Series B - Kolltan Pharmaceuticals
Elm Street Ventures
Elm Street Ventures investment in Series A - Kolltan Pharmaceuticals
Official Site Inspections
http://www.kolltan.com
- Host name: underconstruction.networksolutions.com
- IP address: 205.178.189.129
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
